Latest News
- New Direct Tax Transfer Mechanism For Vehicle Imports
- Citizen Arrested For Illicit Marijuana Farming In Salwa Apartmen...
- MoE Prioritizes Local Hiring To Address Teacher Shortage
- Court Sentences Bank Employee To 5 Years For Embezzling 100,000...
- Fake ‘Sheikh’ Sentenced To 2-yr As Court Overturns Verdict
- Justice Ministry New Service On The Sahel App
- Ministry Probes 68 Cases Of Illegal Charity, Funds Collection
- Globally, Kuwait Is Among The Top Consumers Of Incense And Oud O...
- Decrease Seen In Foreign Investment
- Kuwait Customs Seized 2 Containers Laden With Tobacco At Shuwaik...
- Unpaid Salaries, Accountant Beaten Up By Workers
- The Sahel App Was Not Hacked, A Spokesman Claims
Moderna’s Coronavirus Vaccine Found To Be 94.5 Percent Effective
Biotechnology company Moderna announced Monday that its coronavirus vaccine has found to be 94.5 percent effective in the first interim analysis of the Phase 3 study. In a statement, Moderna said this study, “known as the COVE study, enrolled more than 30,000 participants in the US.”
“The primary endpoint of the Phase 3 COVE study is based on the analysis of COVID-19 cases confirmed and adjudicated starting two weeks following the second dose of vaccine,” it indicated. “This first interim analysis was based on 95 cases, of which 90 cases of COVID-19 were observed in the placebo group versus five cases observed in the (vaccine) group, resulting in a point estimate of vaccine efficacy of 94.5 percent.”
“Preliminary analysis suggests a broadly consistent safety and efficacy profile across all evaluated subgroups,” it affirmed. Chief Executive Officer of Moderna Stephane Bancel said “this is a pivotal moment in the development of our COVID-19 vaccine candidate.” “Based on these interim safety and efficacy data, Moderna intends to submit for an Emergency Use Authorization (EUA) with the USFood and Drug Administration (FDA) in the coming weeks,” the company noted. It added that it “anticipates having the EUA informed by the final safety and efficacy data (with a median duration of at least 2 months).”
It indicated that by the end of 2020, it expects to have about 20 million doses ready to ship in the US and that it “remains on track” to manufacture 500 million to one billion doses globally in 2021. Last week, Pfizer announced that early data showed its coronavirus vaccine to more than 90 percent effective.
SOURCE: TIMESKUWAIT
Trending News
-
Eid Al Fitr 2024: Crescent Moon Not Sighted In Sau...
08 April 2024
-
Kuwait Implements Home Biometrics Services Ahead O...
14 April 2024
-
When Will Eid Al Fitr 2024 Take Place In Qatar, Ba...
08 April 2024
-
On Sunday, The Meteorological Department Warns Of...
07 April 2024
-
Kuwait Airways Provides Update On Flight Schedule...
14 April 2024
-
Kuwait Airways Introduces Convenient Home Luggage...
15 April 2024
-
Gathering For Eid Al-Fitr Prayers: Kuwaiti Citizen...
10 April 2024
-
Winners Of Kuwait National Assembly 2024 Elections
06 April 2024
-
Bay Zero Water Park Kuwait: Summer Season Opens Ei...
11 April 2024
-
An Egyptian Expat Dies At Kuwait's Airport
11 April 2024
Comments Post Comment